Case Report: Bilateral symmetrical primary kaposiform hemangioendothelioma of the femur

Tong Qiu1,2†, Yuru Lan1,2†, Jiangyuan Zhou1,2, Kaiying Yang1,2, Xue Gong1,2, Zixin Zhang1,2, Siyuan Chen3 and Yi Ji1,2⁎

1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China, 2Med-X Center for Informatics, Sichuan University, Chengdu, China, 3Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China

Kaposiform hemangioendothelioma (KHE) is a rare borderline vascular tumor that usually presents as a mass of skin or deep soft tissue. We report a unique case of an 8-year-old KHE patient with bilateral symmetrical sites involving both femurs. The laboratory, radiographic, and pathological findings of the patient were minutely described. During the 6-month follow-up, the symptoms of pain and dysfunction of this patient were relieved. This study aimed to arouse clinicians’ concern about the symmetrical sites of KHE patients.

KEYWORDS
kaposiform hemangioendothelioma, bone, case report, Kasabach–Merritt phenomenon, pediatric

Introduction

Kaposiform hemangioendothelioma (KHE) is a rare borderline tumor with locally invasive features, which are mostly seen in children and adolescents, with an incidence of 0.71/100,000 (1). Clinical manifestations are more involved in the skin of the purplish red hard mass, and the surrounding tissue clearance is not clear. Only 10% of KHE patients showed deep lesions without skin involvement, while primary bone lesions were rarer, and most of the lesions were single lesions (2, 3). We report a unique case of KHE symmetrically involving both femurs, accompanied by pain and claudication, who was misdiagnosed as synovitis at an early stage. We aimed to alert clinicians to the early identification of KHE patients at specific sites, which is important for the management and prognosis of KHE patients.

Case description

An 8-year-old female child was referred to our tertiary medical institution for pain and discomfort in both knees accompanied by claudication. Before admission to our hospital, she was treated for “joint synovitis” with anti-inflammatory treatment in a local hospital. The pain symptoms were relieved once, but the pain accompanied by
The patient showed local tenderness and percussion pain on both knees, but with no redness or palpable mass. Additionally, she showed no abnormal vital signs, such as fever and weight loss.

Laboratory tests, including white blood cell count of 12.56 × 10^9/L (reference value was 4.3 × 10^9/L–11.3 × 10^9/L), D-dimer of 0.90 mg/L (reference value was lower than 0.55 mg/L FEU), and C-reactive protein of 8.24 mg/L (reference value was lower than 5.00 mg/L), were mildly abnormal. Other tests, such as blood count, coagulation function, biochemical electrolyte, various metabolic indicators (including thyroid hormone- and bone metabolism-related indicators), erythrocyte sedimentation rate, antigen indicators of parasites, and various immune antibody indicators, were negative.

Imaging examinations included bilateral knee x-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), and whole-body bone imaging (Figures 1–3). Plain radiography and CT of both knee joints indicated uneven bone density in the bilateral femoral diaphysis, epiphysis, and proximal tibia, with multiple low-density sites and calcification. However, the joint space showed no obvious narrowing. MRI indicated that lump-shaped shadows with heterogeneous internal tissue could be seen in cancellous bone after opening the bone cortex window. Postoperative pathology results showed positivity for CD31, SMA, Ki-67, CD34, FA-8, ERG, and D2-40, and negativity for NSE (Figure 4). The above immunohistochemical and histological morphology results all supported the diagnosis of KHE.

After surgery, the patient was given oral sirolimus (0.8 mg/m²) monotherapy daily, and the blood concentration of sirolimus was maintained in the range of 3–8 ng/ml during the follow-up. Fortunately, the symptoms of claudication disappeared, and the hematological results completely returned to normal after a period of 6 months.

**Discussion**

KHE can be divided into superficial, mixed, and deep types, and the most common one is the mixed type (4, 5). Nearly 70% of KHE cases can be accompanied by the Kasabach–Merritt phenomenon (KMP) of severe thrombocytopenia and coagulopathy (1). Although 62.8% of KHE patients were reported to have musculoskeletal diseases, most of the KHE lesions were deep soft tissue that invaded bones. Lesions primarily originating from bone and limited inside bone are very rare (6). Among a series of 31 KHE patients, Kuo et al. reported that there were six primary bone KHE cases involving the unilateral limb bones, spine, sacrum, scapula, and sternum (3). To the best of our knowledge, the KHE case involving bilateral femur symmetry reported in this study is the first to be reported in the literature world.

Among the 107 KHE patients reported by Croteau et al., only 3 cases were confined to bone without KMP (1). Additionally, in our case report, blood coagulation function was approximately normal, and KMP did not appear. This might be because the lesions are confined to the bone, and the soft tissue around the lower femurs on both sides was not involved. There was no periosteal reaction, and the lesions may be physically limited by the cortical bone, which could not be further invaded. The risk of KMP was smaller than that of skin and muscle lesions.

The most common lesions of KHE occur in limbs (7). However, in current studies on KHE, there were no cases with symmetric limbs involved and confined to the bone. Bilateral intraosseous lesions can be easily misattributed to osteomyelitis, fibrous dysplasia, and so on, which are caused by other bone diseases.
by trauma, infection, or abnormal growth in clinical practice. The diagnosis of KHE depended on the comprehensive evaluation of clinical manifestations, hematology, imaging, and pathological results. The diagnosis of KHE can often be ignored and delayed for such rare symmetrical lesions, resulting in significant disability and mortality rates.
Therefore, definite diagnosis through biopsy is particularly important for treatment direction, which can reduce the long-term complications of KHE.

Extensive resection of the lesion was not recommended for the KHE patient we reported to have bilateral femur lesions, which might lead to long-term complications and disability. Sirolimus is currently the first-line treatment for KHE (8–10). In our previous study, it was found that patients receiving sirolimus plus prednisolone therapy had fewer blood transfusions and a lower overall incidence of disease sequelae than those receiving sirolimus monotherapy. Sirolimus plus prednisolone is considered to be an effective treatment for KHE with KMP (2). We usually used sirolimus plus prednisolone to treat KHE patients with KMP, but for bone KHE patients without KMP, monotherapy with the mTOR inhibitor sirolimus acting on the PI3K/AKT/mTOR signaling pathway through inhibition of angiogenesis and lymphangiogenesis can effectively control and reduce mass and complications (11, 12).

**Conclusion**

In conclusion, we should also be alert to the possibility of KHE of symmetry osteopathy in the clinic. Biopsy is the gold standard for clear diagnosis of this challenging disease. Early and timely diagnosis is crucial for the prognosis of complications such as pain and dysfunction and the quality of life of children.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

**Ethics statement**

The studies involving human participants were reviewed and approved by the Ethics Committee on Medical Research of West China Hospital, Sichuan University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**Author contributions**

TQ, YL, and YJ contributed to the conception and design. All authors contributed to the collection and assembly of data. TQ and YL contributed to the manuscript preparation. SC and TQ contributed to the manuscript editing. YJ contributed to the manuscript revision/review. All authors contributed to the article and approved the submitted version.

**Funding**

This work was supported by the Key Project in the Science & Technology Program of Sichuan Province (grant numbers 2022YS0233, 2022YS0225, and 2019YS0322), the Project of “0 to 1” of Sichuan University (grant number 2022SCUH0033), Med-X Center for Informatics Funding Project (YGJC004), and the 1-3-5 Project for Disciplines of Excellence Clinical Research Incubation Project, West China Hospital of Sichuan University (grant numbers ZYJC21060, 2020HXXF048, and 2019HXXF056).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. *J Pediatr.* (2013) 162(1):142–7. doi: 10.1016/j.jpeds.2012.06.044

2. Ji Y, Chen S, Zhou J, Yang K, Zhang X, Xiang B, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. *Blood.* (2022) 139(11):1619–30. doi: 10.1182/blood.2021014027

3. Kuo C, Warren M, Malvar J, Miller JM, Shah R, Navid F, et al. Kaposiform hemangioendothelioma of the bone in children and adolescents. *Pediatr Blood Cancer.* (2022) 69(3):e29392. doi: 10.1002/pbc.29392

4. Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study. *Int J Cancer.* (2017) 141(4):848–55. doi: 10.1002/ijc.30775

5. Ji Y, Yang K, Peng S, Chen S, Xiang B, Xu Z, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon. *Br J Dermatol.* (2018) 179(2):457–63. doi: 10.1111/bjd.16603

6. Boccaaro O, Dangien A, Fitoussi F, Ducou Le Pointe H, Coulomb L’Hermine A, Fraïttag S, et al. Bone kaposiform hemangioendothelioma: a rare entity dramatically improved by sirolimus. *J Paediatr Child Health.* (2022) 58(9):1676–9. doi: 10.1111/jpc.15897

7. Zhou J, Yang K, Dai S, Qiu T, Zhang X, Gong X, et al. Clinical features and management of kaposiform hemangioendothelioma and tufted angioma: similarities and differences. *J Am Acad Dermatol.* (2022) 87(1):172–4. doi: 10.1016/j.jaad.2021.07.012

8. Blatt J, Stavas J, Moats-Staats B, Woonse J, Morrell DS. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. *Pediatr Blood Cancer.* (2010) 55(7):1396–8. doi: 10.1002/pbc.22766

9. Oza VS, Manlouk MD, Hess CP, Mathes EF, Frieden IJ. Role of sirolimus in advanced kaposiform hemangioendothelioma. *Pediatr Dermatol.* (2016) 33(2):e88–92. doi: 10.1111/pde.12797

10. Wang Z, Li K, Dong K, Xiao X, Zheng S. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. *J Pediatr Hematol Oncol.* (2015) 37(1):72–3. doi: 10.1097/MPH.0000000000000668

11. Qiu T, Yang K, Dai S, Chen S, Ji Y. Case report: kaposiform hemangioendothelioma with spinal involvement. *Front Pediatr.* (2021) 9:600115. doi: 10.3389/fped.2021.600115

12. Ji Y, Chen S, Yang K, Xia C, Li L. Kaposiform hemangioendothelioma: current knowledge and future perspectives. *Orphanet J Rare Dis.* (2020) 15(1):39. doi: 10.1186/s13023-020-1320-1